Abstract
Polymorphisms in carcinogen- and drug-metabolizing enzymes may increase the risk of acute myeloid leukemia (AML) and may influence prognosis. We report that the polymorphic variant of the cytochrome P450 CYP1A1*2A, present in 11.3% of patients, is an independent unfavorable prognostic factor for failure-free and overall survival in patients with AML.
Vol. 90 No. 7 (2005): July, 2005 : Letters to the Editor
Published By
Ferrata Storti Foundation, Pavia, Italy
